SIGRID THERAPEUTICS
Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.
SIGRID THERAPEUTICS
Industry:
Biotechnology Medical Device
Founded:
2014-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.sigridthx.com
Total Employee:
11+
Status:
Active
Contact:
+46723893396
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Dice Therapeutics
Dice Therapeutics develops a transformative platform designed for the discovery of novel small molecules.
Bolder Surgical
Bolder Surgical serves health care providers by developing surgical instruments that allow access to confined and delicate structures.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Tandem Diabetes Care
Tandem diabetes care provides products that empower both people with diabetes and those who care for them.
Current Employees Featured
Founder
Investors List
Joyance Partners
Joyance Partners investment in Venture Round - Sigrid Therapeutics
Crosslight Partners
Crosslight Partners investment in Venture Round - Sigrid Therapeutics
Irrus Investments
Irrus Investments investment in Venture Round - Sigrid Therapeutics
Hans and Barbara Bergström
Hans and Barbara Bergström investment in Venture Round - Sigrid Therapeutics
Social Starts
Social Starts investment in Venture Round - Sigrid Therapeutics
Pär Gellerfors
Pär Gellerfors investment in Venture Round - Sigrid Therapeutics
Newest Events participated
Official Site Inspections
http://www.sigridthx.com
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Sigrid Therapeutics"
Sigrid Therapeutics - Crunchbase Company Profile & Funding
Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.See details»
Sigrid Therapeutics announces appointment of distinguished …
May 9, 2023 /CNW/ -- Sigrid Therapeutics (Sigrid), a Swedish consumer-centric Healthtech company today announced it has appointed world-leading oral health expert...See details»
Unique Swedish concept for two of the world’s biggest …
Nov 8, 2021 At the same time, for the second year in a row, Sigrid Therapeutics’ CEO Sana Alajmovic has been appointed one of the female leaders of the Future by the management organization Ledarna. The award is given to female …See details»
Sigrid Therapeutics Announces Collaboration with Cencora to …
Jan 25, 2024 Sigrid Therapeutics, a clinical-stage healthtech company dedicated to revolutionizing the management of obesity and diabetes prevention with a novel, fast-acting, …See details»
Sigrid Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Sigrid Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Sigrid Therapeutics - VentureRadar
Nov 1, 2020 "Sigrid Therapeutics is a clinical-stage biotechnology company pioneering a new class of therapies to prevent and treat lifestyle diseases. The Company developed a novel …See details»
Sigrid Therapeutics - Company Profile - Tracxn
Feb 25, 2025 Sigrid Therapeutics - Developer of therapies to treat metabolic and chronic lifestyle diseases. Raised a total funding of $17.5M over 5 rounds from 10 investors.See details»
Sigrid Therapeutics Secures $4 Million in Oversubscribed
Oct 31, 2023 /CNW/ -- Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors,...See details»
Sigrid Therapeutics Secures $4 Million in Oversubscribed
Oct 31, 2023 Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong …See details»
Sigrid Therapeutics Announces Collaboration with …
Jan 25, 2024 Stockholm, Sweden – Thursday January 25, 2024. Sigrid Therapeutics, a clinical-stage healthtech company dedicated to revolutionizing the management of obesity and diabetes prevention with a novel, fast-acting, non …See details»
Sigrid Therapeutics Secures $4 Million in ... - Markets Insider
Oct 31, 2023 Sigrid Therapeutics Secures $4 Million in Oversubscribed Funding Round to Tap Into Booming Obesity and Diabetes MarketSee details»
Sigrid Therapeutics | VentureRadar
Sigrid Therapeutics is a clinical-stage biotechnology company pioneering a new class of therapies to prevent and treat lifestyle diseases. The Company developed a novel materials platform …See details»
Sigrid Therapeutics Company Information - Funding, Investors, …
Get information on funding, investors, industries, and more for Sigrid Therapeutics. See Sigrid Therapeutics company profile and funding data.See details»
Sigrid Therapeutics raises further SEK10.6 million in …
Jan 17, 2023 Sigrid Therapeutics raises further SEK10.6 million in oversubscribed rights issue for accelerated SiPore® commercialization Swedish Health and Wellbeing company on track …See details»
Sigrid Therapeutics Announces First Patient Treated with SiPore21 ...
Oct 9, 2023 /PRNewswire/ -- Sigrid Therapeutics announces the commencement of the SHINE clinical trial for SiPore21® – an innovative medical device designed for sustained...See details»
Sigrid Therapeutics’ Co-founder & CEO Sana Alajmovic named …
Nov 29, 2021 Amidst fierce competition from other stars of Sweden’s booming start-up scene, Sana Alajmovic, founder and CEO of healthtech company Sigrid Therapeutics, was voted the …See details»
Sigrid Therapeutics Announces First Patient Treated with SiPore21 ...
Oct 9, 2023 Sigrid Therapeutics announces the commencement of the SHINE clinical trial for SiPore21® – an innovative medical device designed for sustained diabetes and weight control.See details»
Microsoft Word - CPL WEBINAR NOTES ENG[1].docx - sigridthx.com
If anything is unclear, please feel free to contact us at: [email protected] On the 14th of October we will send out a second survey to you via email from the company Novacommerce.See details»
Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its ...
Apr 30, 2024 SHINE is the largest ongoing clinical study of its kind, marking a milestone in research on prediabetes and weight control. It involves individuals who are living with excess …See details»